Further strategies, including the transfer of WT1-specific T-cells or autologous vaccination of AML patients with the WT1 peptide, did increase anti-leukemia immune responses in relapsed or high-risk leukemia patients [203,207,209]. The gene discussed is WT1; the disease is acute myeloid leukemia.